Last reviewed · How we verify
RELVAR/BREO
RELVAR/BREO is a combination inhaler containing fluticasone furoate (an inhaled corticosteroid) and vilanterol (a long-acting beta-2 agonist) that reduces airway inflammation and improves bronchodilation in chronic obstructive pulmonary disease.
RELVAR/BREO is a combination inhaler containing fluticasone furoate (an inhaled corticosteroid) and vilanterol (a long-acting beta-2 agonist) that reduces airway inflammation and improves bronchodilation in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma maintenance treatment (in some markets).
At a glance
| Generic name | RELVAR/BREO |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination |
| Target | Glucocorticoid receptor; beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Fluticasone furoate binds to glucocorticoid receptors in the airways, suppressing inflammatory responses and reducing mucus production. Vilanterol activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and improving airflow. Together, these agents provide both anti-inflammatory and bronchodilatory effects in a single maintenance inhaler.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Asthma maintenance treatment (in some markets)
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness
Key clinical trials
- A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma (PHASE3)
- A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |